How AbbVie Leverages DHTs To Improve Data Collection And Analysis In Immunology Clinical Trials

Wearable digital health technologies (DHTs) are transforming how physical activity limitations in patients with immunological diseases are assessed. These conditions often restrict mobility and impact daily functioning, making objective measurement of patient activity crucial for improving quality of life and advancing drug development.

In this Digital Health Monthly session of 2025, Jie Shen, PhD, MBA, Research Fellow and Director of Digital Science at AbbVie, present “Profiling Physical Activities of Patients with Immunological Diseases.” Dr. Shen explores how AbbVie is leveraging DHTs to enhance clinical trial methodologies, address unmet needs in immunology drug development, and refine outcome assessments. He highlights clinical validation data from DHT applications in two patient populations, demonstrating how real-world activity data can be effectively collected, analyzed, and integrated into research trials to support more precise and patient-centered therapeutic advancements.